Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07142798

to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection

To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

HELICOBACTER PYLORI INFECTIONS

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kaohsiung Medical University Hospital

Kaohsiung City, 807, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects infected with Helicobacter pylori.

Exclusion criteria

  • Those who are allergic to the drugs used in this research.
  • Those who have had stomach surgery.
  • Those with severe liver cirrhosis or uremia or malignant tumors.
  • Women who are pregnant or breastfeeding. If you have drug allergies or pregnant women or breast-feeding women during the test period, you can withdraw from the test early.

Treatment and study plan

Bismuth amoxilillin potassium

Drug

vonoprazan 20mg， Twice a day amoxicillin 750mg，Four times a day tripotassium dicitrate bismuthate 300mg，Four times a day for 14 days

Primary outcomes

  1. Eradicaton rate of Helicobacter pylori

    Time frame: 6 weeks after finishing study drugs

    13CUBT

Secondary outcomes

  1. evaluate side effect

    Time frame: 2days after taking medicine

    evaluate drugy side effect by Questionnaire

Sponsors and collaborators

Lead sponsor

Kaohsiung Medical University

Other

Collaborators

  • An-Nan Hospital, China Medical University

Registry information

Official study title

Efficacy of Bismuth/Amoxicillin/Potassium-competitive Acid Blocker Triple Therapy for the Treatment of Helicobacter Pylori Infection in Taiwan

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Aug 27, 2025
Registry last updated
Aug 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.